Investor Presentation for quarter ended June 30, 2026.

Q1FY27 Investor Presentation Some of the statements made in this presentation are forward-looking statements and are based on the current beliefs, assumptions, expectations, estimates, objectives and projections of the directors and management of Kwality Pharmaceutical Limited about its business, the industry and markets in which it operates. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of the Company and are difficult to predict. Kwality Pharmaceutical Limited does not undertake to update these forward-looking statements to reflect events or circumstances that may arise. ‘; FY27 Guidance Updated METRICS FY26A PREVIOUS FY27 GUIDANCE UPDATED FY27 GUIDANCE CHANGE / UPDATE (us. Previous Guidance) (Actual) REVENUE 503 650 700+ Raised Raised Higher growth (X Crore) (+29%) (+39%+) INR 50 Cr+ visibility Raised E;:\:DA_ 118 176 - 196 189 - 196+ Raised Stronger operating leverage and product mix % Margin) (~23.5% Margin) (27% - 28% Margin) (27% - 28%+ Margin) +13 bps . 67 100 109+ Raised Raised Improved profitability (% Margin) e (~15.3% Margin) (~15.5%+ Margin) +30 bps outlook (~*13.4% Margin) (+190 bps) (+220 bps) WE ARE RAISING THE BAR Increasing our growth and profitability outlook on the back of strong execution and clear visibility Note: YoY growth rates are for FY27 over FY26 All values in INR Cr. g 4 Decades of Expertise and Manufacturing Excellence r rputure Growth: High Margin critical Research + Manufacturing + Quality Excellence Achieved Expertise in Complex Formulation care, Bio-similar and oncology Development & Manufacturing molecules including peptides 1,750+ employees including 90+i n R&D rBroad & Diverse Product Offering r 1000+ formulations across 25+ 4/5 Units EUGMP Approved as per 700+ regulatory filings across many countries therapeutic use 90% Revenue Annex 1 of recent EU guidelines from out-licensing and supplies 20+ audits in the past two years Therapy Areas 70+ countries served, with a diverse global clientele SNSS Beta Lactam Oncology %162 Cr Revenue in Q1FY27, Net Profit X26 Cr 40% Targeting topline growthi n FY27 000009 Cephalosporins Biologics Hormones Revenue growth supported by manufacturing scale-up All values in INR Cr. CAGR :26% l 700+ FY23 FY24 FY25 FY26 FY27E Journey so far... 1983 2018 2020 2022 2023 2024 2025 2026 Company * Manufacturing * Migrated « Established « Established « Initiated « PICs GMP EUGMP approval for general and Founded Facility to BSE Beta lactam Biological Unit development of approval for beta lactam units Dpetadaticy « Developing Uiz * EU GMP for giPoLIol f(t:s lB"e“tta leciEm BE programmes for 40+molecules * PIC/s GMP for vast portfolio * Developed Oncology & g ) ongoing (3+ successfully completed) Injectable facility of Injectables 10+ complex Ce;_)halosponn * 2 BE studies * SFDA approval Sz e s (er L % products Units successfully for General Erythropoetin gRED) /dQ::' facility * Imt'itet‘:_l_ (Microspheres Market il conducted and Beta upgradation market filings Linosoril * Market filings —— N N . ol ? of KPL’s niche * Successful opegecapacbyexpansion * Exports to 40+ Nanoparticle) in biologics and oncology products approval and markets commercializati WHO GMP for Biologics (Drug on in High Substance and regulated Drug Product) markets-EU /S Unit 6 - A dedicated plant for Africa hormones being constructed (Completion by Q3CY26) PAT growing ~3x faster than revenue Revenue Scale Translating into Profit Acceleration Key Levers and their performance over years Key Operational Levers FY23 FY26 Improvement / Status Revenue (% Cr) 251 503 ~2x Cumulative Filings (Nos.) 75 700+ ~1.7x Capacity Utilisation (Overall) ~35% ~65%+ ~1.9x R&D Spend (% of Revenue) Less than 1% ~2.5% Investing for future FY24 FY25 FY26 Working Capital Cycle (Days) 297 161 -136 Days I Revenue PAT —e—Filings All values in INR Cr. Ramesh Arora Ajay Arora Aditya Arora Chairman & Managing Director Director Director AREA OF FOCUS AREA OF FOCUS AREA OF FOCUS IT, Software and Legal Raw material procurement and Quality assurance, Quality Agreements & Proceedings infrastructure development control, Regulatory compliance 42 Years of Experience 31 Years of Experience 11 Years of Experience Hormones is under construction, Ny expected to commence by H2FY26 Successfully completed 20+ 01 regulatory, customer, and vendor audits over the past two years. Proactively upgrades plant 02 = Dractices by benchmarking against Form 483 observations across the industry Centralized CQA team ensures 03 audit learnings are consistently implemented across all manufacturing units @:fi% ed Manufacturing Capabilities Amvritsar Plant (Campus 1) Himachal plant (Campus 2) Oral Solids - Tab/Capsule, Suppositories Oral Solids - Tab/Capsule Ointments/Creams, Oral Liquids Powder for Injection Dental Cartridges Injectables (Vials/Ampoules/PFS) D57 S Sdhi Tablets - 1800 Million Capsules - 180 Million Ampoules - 200 Million Tablets - 3000 Million Vials - 200 Million Capsules - 1500 Million Lyophilized Products - 3 Million Powder for Injection - 50 Dry Powder Injection - 100 Million Million PFS - 1 Million Dry Syrup - 200 Million Dental Cartridge - 40 Million Sachet - 100 Million Suppositories - 40 Million Ointments - 20 Million EU GMP, PICS (Anvisa, EU GMP, PICS (Anvisa, Invima, Sfda, T, [ Ukraine) 1000+ products across key therapies - Broad Dosage form capabilities Revenue Therapies share % Unit wise Revenue Split for Q1FY27 Generals, Beta Lactam, Oncology & Injectables 43% Cephalosporins Generals, Beta Lactam, Oncology & Tablets 40% Cephalosporins Generals, Beta Lactam, Oncology & Capsules 6% Cephalosporins Liquid externals Generals, Beta Lactam, Oncology & and orals Cephalosporins, Biologics Creams and 3% Generals ointments Dry syrups 2% Beta Lactam & Cephalosporins 15% Ophthalmic 1% General 2% 1% Sachets 1% Beta Lactam FY26 mUnitl =Unit2 Unit3 =Unit4 =Unit5 Suppositories 1% General Revenue share Filings o 140 100+ clients across LATAM, MENA, ' Europe, Asia & Africa; FY23 FY24 FY25 FY26 expand via 700+ filings. = Outlicensing and Supply - CDMO # Filings Tie to Moats Leverage achieved Regulatory Approvals : EU GMP, ANVISA (Brazil), INVIMA (Colombia), etc., prove quality for tough markets. Affordable niche focus : Vision targets affordable complex molecules ° with high quality focus Proven growth : Filings jumped from 75 (2022-23) to 200 (2025-26); exports to LATAM, Africa, MENA via licensing. Monetizes in - house product development Enables rapid international expansion Stable export revenues with limited front - end risk g End-to-End Pa ip Driving Hig Boosting talent, attaining expertise “ SHEEEE 80 scientists Proves innovation R&D Head: t eadcoun (DSIR-recognized) muscle Dedicated QA and QC QA & QC team teams function strength s Ao independently across each unit. Liposomal Pegylated 140 145 Injectables, Emulsion Tech Focus Technology, Lyophilized High-margin niches (30 - 40%) Injectables, Long - acting 107 Injectables, Niche Biological ni 922 80 78 300M injectables/year + Serving large and global C it demand apactty biologics Capacity Multi-block (oncology at i Utilization 60-70%) Efficient asset use R&D team QA team QC team Opens almost all the FY23 =FY24 ®FY25 wQI1FY27 markets across the world Applied R&D + Development Engine supporting future CDMO partnerships Core Research Initiatives /;1\ Biosimilars Development ) Hypothesis driven innovation Enhancing existing drug molecules through formulation and process optimization to improve efficacy, safety, and manufacturability for high o N regulated markets. Oncology Research Conducting studies to strengthen capabilities in complex and high-value therapeutic segments (OSD & Injectables) Chronic Disease Research (Exploratory) Early-stage research focused on chronic and lifestyle diseases, supporting long-term specialty pharma and CDMO opportunities. € Infrastructure & Capability Expansion Ongoing investment [Showing first 8,000 characters — download PDF for full document]